Lupin Limited , a global pharmaceutical leader, has announced robust financial results for the second quarter of fiscal year 2026, showcasing significant growth across key metrics.

Financial Highlights

Lupin's consolidated performance for Q2 FY2026 demonstrates substantial year-over-year improvements:

The company's EBITDA margin expanded significantly to 33.20%, up 960 basis points from the previous year, indicating improved operational efficiency.

Segment Performance

Lupin reported strong performance across all markets, including the US, emerging markets, and India.

Operational Highlights

• Lupin's revenue from operations grew 24.20% to ₹7,047.50 crore, surpassing the analyst poll estimate of ₹6,559.40 crore.
• The company's net profit of ₹1,478.00 crore exceeded analyst estimates of ₹1,217.80 crore.

Management Commentary

Mr. Nilesh Gupta, Managing Director of Lupin Limited, described the results as "one of their strongest performances ever" and expressed confidence in delivering a strong FY26.

Market Response

Despite the strong results, Lupin shares ended down 2.11% at ₹1,956.05 on the BSE.

Lupin's impressive Q2 results reflect the company's strategic initiatives and operational excellence, positioning it for continued growth in the global pharmaceutical market.

Lupin Limited , a global pharmaceutical leader, has announced a significant development in its regulatory compliance efforts. The company has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Pithampur Unit-3 facility, marking a positive step in its manufacturing operations.

Inspection Details

The EIR was issued following a thorough inspection of the Pithampur Unit-3 facility, which took place from July 7 to July 17. This facility is crucial to Lupin's operations, as it manufactures a variety of pharmaceutical products including:

• Metered dose inhalers
• Dry powder inhalers
• Topical formulations
• Nasal solutions

Significance of the EIR

The receipt of an EIR is typically an indicator that the FDA has closed its inspection of the facility, finding it to be in an acceptable state of compliance with current good manufacturing practice (cGMP) regulations. This development is particularly important for Lupin, as it reinforces the company's commitment to maintaining high standards of quality and compliance in its manufacturing processes.

Management's Response

Nilesh Gupta, Managing Director of Lupin, expressed satisfaction with the outcome, stating, "We are pleased to have received the EIR from the U.S. FDA for our Pithampur Unit-3 facility. This demonstrates our commitment to maintaining the highest standards of compliance and quality, as we aim to deliver high-quality, affordable medicines from world-class factories for patients worldwide."

About Lupin Limited

Lupin Limited is a prominent player in the global pharmaceutical industry, with a significant presence in over 100 markets. The company specializes in:

With 15 state-of-the-art manufacturing sites and 7 research centers globally, Lupin employs over 24,000 professionals. The company is also expanding its reach through subsidiaries such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

This latest regulatory approval underscores Lupin's ongoing efforts to ensure the highest standards of quality and compliance across its manufacturing facilities, reinforcing its position as a trusted provider of pharmaceutical products in the global market.